# Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

> **NCT06983210** · PHASE2 · RECRUITING · sponsor: **Nagoya University** · enrollment: 43 (estimated)

## Conditions studied

- Urothelial Carcinoma Bladder
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Urothelial Carcinoma Urethra
- Urothelial Carcinoma Recurrent

## Interventions

- **DRUG:** Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy

## Key facts

- **NCT ID:** NCT06983210
- **Lead sponsor:** Nagoya University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983210, "Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06983210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*